Intravitreally Administered Soluble VEGF Receptor-1 Variant Tested as a Potential Gene Therapeutic for Diabetic RetinopathySteven Hyun Seung Lee(Korea Drug Research Association), Heuiran Lee(Asan Medical Center)Advances in Cell and Gene TherapyOctober 13, 202210.1155/2022/9670992Cited by 3SaveCiteExport RISWatch citationsRelated PapersmTOR inhibition as a novel gene therapeutic strategy for diabetic retinopathy|PLoS ONE|2022|13An examination of the mechanisms driving the therapeutic effects of an AAV expressing a soluble variant of VEGF receptor-1|PLoS ONE|2024|1